by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

Jubilant HollisterStier General Partnership Warning Letter Details

Warning Letter

Jubilant HollisterStier General Partnership

Recipient Title President, Chief Executive Officer, Jubilant HollisterStier General Partnership, 16751 Trans-Canada Highway Kirkland QC H9H 4J4 Canada

Issue DateMay 28, 2026

FEI Number3001623073

Violations2

CountryCanada

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

CGMP/Finished Pharmaceuticals/Adulterated

Jubilant HollisterStier General Partnership FDA Warning Letter, May 28, 2026